GAUSS-3: Evolocumab Outperforms Ezetimibe in Certain Statin-Intolerant Patients
Evolocumab significantly reduced LDL-C at 24 weeks in patients with statin intolerance related to adverse events compared with ezetimibe.
Evolocumab significantly reduced LDL-C at 24 weeks in patients with statin intolerance related to adverse events compared with ezetimibe.
Evacetrapib did lower low-density lipoprotein cholesterol in high vascular risk patients, but did not reduce major cardiovascular events.
In patients who were at high risk for cardiovascular disease, 25% of those from Puerto Rican and Dominican backgrounds used statins and less than half used aspirin.
Researchers concluded that approximately 834 500 Americans have this inherited condition.
Tai chi, qigong, and other traditional Chinese exercises appeared to improve quality of life and reduce depression in patients with cardiovascular disease.
In metabolomic profiling study, statins were found to affect more extensive lipid changes beyond low-density lipoprotein cholesterol.
Coronary heart disease patients with high triglyceride levels have an increased 22-year mortality risk, independent of high-density lipoprotein cholesterol levels.
National Health and Nutrition Examination Survey data from 1999 to 2012 were analyzed and revealed a decline in metabolic syndrome in US adolescents (aged 12 to 19 years).
Target low-density lipoprotein cholesterol levels were more likely achieved in cardiology and endocrinology departments and at higher potency levels.